Washington city alleges drugmaker allowed OxyContin to flood black market

EVERETT, Wash. — As deaths from painkillers and heroin abuse spiked and street crimes increased, the mayor of Everett took major steps to tackle the opioid epidemic devastating this working-class city north of Seattle.

Mayor Ray Stephanson stepped up patrols, hired social workers to ride with officers and pushed for more permanent housing for chronically homeless people. The city says it has spent millions combating OxyContin and heroin abuse — and expects the tab to rise.

So Everett is suing Purdue Pharma, maker of the opioid pain medication OxyContin, in an unusual case that alleges the drugmaker knowingly allowed pills to be funneled into the black market and the city of about 108,000. Everett alleges the drugmaker did nothing to stop it and must pay for damages caused to the community.

Everett’s lawsuit, now in federal court in Seattle, accuses Purdue Pharma of gross negligence and nuisance. The city seeks to hold the company accountable, the lawsuit alleges, for “supplying OxyContin to obviously suspicious pharmacies and physicians and enabling the illegal diversion of OxyContin into the black market” and into Everett, despite a company program to track suspicious flows.

“Our community has been significantly damaged, and we need to be made whole,” said Stephanson, who grew up in Everett and is its longest-serving mayor, holding the job since 2003.

He said the opioid crisis caused by “Purdue’s drive for profit” has overwhelmed the city’s resources, stretching everyone from first responders to park crews who clean up discarded syringes. The lawsuit doesn’t say how much money the city is seeking, but the mayor says Everett will attempt to quantify its costs in coming months.

Connecticut-based Purdue Pharma says the lawsuit paints a flawed and inaccurate picture of the events that led to the crisis in Everett.

“We look forward to presenting the facts in court,” the company said in a statement.

Purdue said it is “deeply troubled by the abuse and misuse of our medication,” and noted it leads the industry in developing medicines with properties that deter abuse, even though its products account for less than 2 percent of all U.S. opioid prescriptions.